6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Immune checkpoint molecules are regulated by transforming growth factor (TGF)- β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with a high mortality rate. Epithelial-to-mesenchymal transition (EMT) confers cancer cells with immune evasive ability by modulating the expression of immune checkpoints in many cancers. Thus, the aim of our study is to examine the interplay between EMT and immune checkpoint molecules in HCC. A reversible EMT model was utilised with transforming growth factor (TGF)- β1 as an EMT inducer for HCC cell lines Hep3B and PLC/PRF/5. HCC cells were treated with TGF- β1 for 72 h and the EMT status and immune checkpoint expression were examined. In addition, the migratory ability of HCC cells were examined using wound healing and transwell migration assays in the reversible EMT model. siRNA-mediated knockdown of immune checkpoint molecule, B7-H3, was further utilised to validate the association between TGF- β1-mediated EMT and immune checkpoint expression in HCC. In addition, a web-based platform, SurvExpress, was utilised to evaluate the association between expression of TGF- β1 in combination with immune checkpoint molecules and overall survival in HCC patients. We observed induction of EMT upon treatment of HCC cells with TGF- β1 revealed by reduced expression of epithelial markers along with increased expression of mesenchymal markers. Withdrawal of TGF- β1 reversed the process of EMT with elevated expression of epithelial markers and reduced expression of mesenchymal markers. TGF- β1 treatment elevated the migratory potential of HCC cells which was reversed following reversal assay. Notably, during TGF- β1-induced EMT, there was upregulation of immune checkpoint molecules PD-L1 and B7-H3. However, the reversal of EMT decreased the expression of PD-L1 and B7-H3. In addition, TGF- β1 driven EMT was reversed following knockdown of B7-H3 in both HCC cells further validating the interplay between TGF- β1-mediated EMT and immune checkpoint expression in HCC. Furthermore, the coordinate expression of TGF- β1 with PD-L1 ( p=0.01487) and B7-H3 ( p=0.009687) was correlated with poor overall survival in 422 HCC patients. Our study has demonstrated a close association between TGF- β1-mediated EMT and regulation of immune checkpoints in HCC.

          Related collections

          Most cited references78

          • Record: found
          • Abstract: found
          • Article: not found

          Epithelial-mesenchymal transitions in development and disease.

          The epithelial to mesenchymal transition (EMT) plays crucial roles in the formation of the body plan and in the differentiation of multiple tissues and organs. EMT also contributes to tissue repair, but it can adversely cause organ fibrosis and promote carcinoma progression through a variety of mechanisms. EMT endows cells with migratory and invasive properties, induces stem cell properties, prevents apoptosis and senescence, and contributes to immunosuppression. Thus, the mesenchymal state is associated with the capacity of cells to migrate to distant organs and maintain stemness, allowing their subsequent differentiation into multiple cell types during development and the initiation of metastasis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

            New England Journal of Medicine, 373(2), 123-135
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Hepatocellular Carcinoma

                Bookmark

                Author and article information

                Journal
                Int J Med Sci
                Int J Med Sci
                ijms
                International Journal of Medical Sciences
                Ivyspring International Publisher (Sydney )
                1449-1907
                2021
                22 April 2021
                : 18
                : 12
                : 2466-2479
                Affiliations
                [1 ]Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
                [2 ]Gallipoli Medical Research Institute, Greenslopes Private Hospital, Brisbane, Queensland, Australia.
                [3 ]Fiona Elsey Cancer Research Institute, Ballarat, Victoria, Australia.
                Author notes
                ✉ Corresponding author: Aparna Jayachandran, PhD, Fiona Elsey Cancer Research Institute, Ballarat Technology Park- Central Suite 23, 106-110 Lydiard St Sth, Ballarat, VIC 3350, Australia. E-mail: aparna@ 123456fecri.org.au ; Phone +61 4 2424 8058.

                Competing Interests: The authors have declared that no competing interest exists.

                Article
                ijmsv18p2466
                10.7150/ijms.54239
                8176170
                34104078
                877db287-fefb-4d4e-b053-e500c5923555
                © The author(s)

                This is an open access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

                History
                : 8 October 2020
                : 30 March 2021
                Categories
                Research Paper

                Medicine
                immune checkpoint molecules,epithelial-to-mesenchymal transition,transforming growth factor-β1,hepatocellular carcinoma

                Comments

                Comment on this article